US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Skye Bioscience Inc.

1.08

-0.0100-0.92%

Volume:367.80K

Turnover:395.83K

Market Cap:34.62M

PE:-0.84

High:1.13

Open:1.11

Low:1.04

Close:1.09

52wk High:5.75

52wk Low:1.04

Shares:32.06M

Float Shares:19.69M

Volume Ratio:1.58

T/O Rate:1.87%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.2914

EPS(LYR):-0.7281

ROE:-94.31%

ROA:-54.88%

PB:1.05

PE(LYR):-1.48

Loading ...

Overview Company News Filings

Skye Bioscience Faces Investor Class Action Over Securities Fraud Allegations

Skye Bioscience Unveils Presentation Highlighting Nimacimab’s Potential to Enhance Obesity Treatments

Skye Bioscience to Participate in Major Healthcare Investment Conferences

Skye Bioscience Showcases New Obesity Drug Data Highlighting Add-On Benefits to GLP-1 Therapies

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR) and Skye Bioscience (SKYE)

Oppenheimer Sticks to Their Buy Rating for Skye Bioscience (SKYE)

Press Release: Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update

Analysts Offer Insights on Healthcare Companies: Skye Bioscience (SKYE) and IN8bio (INAB)

Skye Bioscience Inc expected to post a loss of 31 cents a share - Earnings Preview

Skye Bioscience Inc : Piper Sandler Cuts Target Price to $13 From $20

THOMSON REUTERS

Citizens JMP Remains a Buy on Skye Bioscience (SKYE)

Craig Hallum Downgrades Skye Bioscience to Hold From Buy, $2 Price Target

MT Newswires Live

Skye Bioscience downgraded to Hold from Buy at Craig-Hallum

Skye Bioscience downgraded to Neutral from Overweight at Cantor Fitzgerald

Skye Bioscience Shares Slide as Weight-Loss Drug Candidate Misses Primary Endpoint

Skye Bioscience says nimacimab did not meet primary endpoint in CBeyond study

Skye Bioscience's obesity drug fails to meet main goal of mid-stage study

BRIEF-Skye Bioscience reports early trial data for Cbeyond combo and solo use of Nimacimab

Skye Bioscience Inc - Expects to Report Data From Extension Study in Q1 2026

THOMSON REUTERS

Skye Bioscience Inc - Additional Weight Loss With Nimacimab and Semaglutide Combination

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SKYE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SKYE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SKYE\",,,,,undefined,":{"symbol":"SKYE","market":"US","secType":"STK","nameCN":"Skye Bioscience Inc.","latestPrice":1.08,"timestamp":1765832400000,"preClose":1.09,"halted":0,"volume":367802,"delay":0,"floatShares":19689100,"shares":32057500,"eps":-1.291415,"marketStatus":"Pre-Mkt","change":-0.01,"latestTime":"12-16 05:25:26 EST","open":1.11,"high":1.13,"low":1.04,"amount":395832.374321,"amplitude":0.082569,"askPrice":1.19,"askSize":200,"bidPrice":0.9603,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.291415,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765895400000},"marketStatusCode":1,"symbolChange":{"newSymbol":"SKYED","executeDate":"2023-09-08"},"adr":0,"exchange":"NASDAQ","adjPreClose":1.08,"postHourTrading":{"tag":"盘后","latestPrice":1.07,"preClose":1.08,"latestTime":"18:55 EST","volume":676,"amount":726.26,"timestamp":1765842949629},"volumeRatio":1.575434930459633,"impliedVol":1.1162,"impliedVolPercentile":0.1566},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SKYE\",,,,,undefined,":{"symbol":"SKYE","floatShares":19689100,"roa":"-54.88%","roe":"-94.31%","lyrEps":-0.728135,"volumeRatio":1.575434930459633,"shares":32057500,"dividePrice":0,"high":1.13,"amplitude":0.082569,"preClose":1.09,"low":1.04,"week52Low":1.04,"pbRate":"1.05","week52High":5.75,"institutionHeld":0,"latestPrice":1.08,"committee":-0.333333,"eps":-1.291415,"divideRate":0,"volume":367802,"delay":0,"ttmEps":-1.291415,"open":1.11,"prevYearClose":2.83,"prevWeekClose":1.09,"prevMonthClose":1.31,"prevQuarterClose":3.93,"fiveDayClose":1.21,"twentyDayClose":1.3,"sixtyDayClose":4},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SKYE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-10","symbol":"SKYE","fiscalQuarterEnding":"2025/09","expectedEps":-0.33,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"post","actualEps":-0.32},{"market":"US","date":"2025-08-07","symbol":"SKYE","fiscalQuarterEnding":"2025/06","expectedEps":-0.34,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"post","actualEps":-0.44},{"market":"US","date":"2025-05-08","symbol":"SKYE","fiscalQuarterEnding":"2025/03","expectedEps":-0.31,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":-0.28},{"market":"US","date":"2025-03-20","symbol":"SKYE","fiscalQuarterEnding":"2024/12","expectedEps":-0.3,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742443200000,"reportTimeType":"post","actualEps":-0.24},{"market":"US","date":"2024-11-07","symbol":"SKYE","fiscalQuarterEnding":"2024/09","expectedEps":-0.26,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-0.22}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SKYE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SKYE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.625,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.625,"analysts":8,"updateTime":1759899600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SKYE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SKYE","date":"2025-12-15","current":-0.836292,"percent":1,"low":-12.94129,"twenty":-5.025912,"median":-3.570795,"eighty":-2.015962,"high":-0.682083,"avg":-3.935188,"sd":2.469746,"marketCap":34942632},"quantilePoints":[{"date":"2024-04-12","current":-9.459964,"twenty":-9.513638,"median":-9.459964,"eighty":-7.885539,"marketCap":356118289},{"date":"2024-04-19","current":-12.650558,"twenty":-12.435864,"median":-9.657512,"eighty":-9.495746,"marketCap":476227531},{"date":"2024-04-26","current":-9.579238,"twenty":-12.081022,"median":-9.691058,"eighty":-9.561347,"marketCap":360608354},{"date":"2024-05-03","current":-9.683603,"twenty":-11.635233,"median":-9.68733,"eighty":-9.561347,"marketCap":364537161},{"date":"2024-05-10","current":-8.997775,"twenty":-10.807766,"median":-9.638876,"eighty":-9.507673,"marketCap":338719287},{"date":"2024-05-17","current":-9.168,"twenty":-10.15772,"median":-9.601602,"eighty":-9.22813,"marketCap":343770610},{"date":"2024-05-24","current":-8.952556,"twenty":-9.700003,"median":-9.54942,"eighty":-8.9931,"marketCap":335692167},{"date":"2024-05-31","current":-8.720508,"twenty":-9.691058,"median":-9.489815,"eighty":-8.983995,"marketCap":326991116},{"date":"2024-06-07","current":-8.47349,"twenty":-9.691058,"median":-9.389145,"eighty":-8.952556,"marketCap":317728707},{"date":"2024-06-14","current":-8.069277,"twenty":-9.691058,"median":-9.18753,"eighty":-8.690567,"marketCap":302572037},{"date":"2024-06-21","current":-6.684476,"twenty":-9.685094,"median":-9.060284,"eighty":-8.473188,"marketCap":250646409},{"date":"2024-06-28","current":-5.434411,"twenty":-9.674658,"median":-9.022864,"eighty":-8.245631,"marketCap":203773004},{"date":"2024-07-05","current":-5.58412,"twenty":-9.638876,"median":-8.993879,"eighty":-7.844715,"marketCap":209386586},{"date":"2024-07-12","current":-4.873005,"twenty":-9.631421,"median":-8.980898,"eighty":-7.11863,"marketCap":182722074},{"date":"2024-07-15","current":-4.820607,"twenty":-9.62993,"median":-8.974213,"eighty":-6.892464,"marketCap":180757321},{"date":"2024-08-02","current":-4.102007,"twenty":-9.628439,"median":-8.967527,"eighty":-6.745055,"marketCap":153812130},{"date":"2024-08-09","current":-3.735222,"twenty":-9.606075,"median":-8.870216,"eighty":-5.58412,"marketCap":140058855},{"date":"2024-08-16","current":-3.615791,"twenty":-9.579238,"median":-8.690567,"eighty":-4.690361,"marketCap":152904981},{"date":"2024-08-23","current":-3.787972,"twenty":-9.567311,"median":-8.506414,"eighty":-4.17237,"marketCap":160186171},{"date":"2024-08-30","current":-4.584307,"twenty":-9.543456,"median":-8.189044,"eighty":-4.185844,"marketCap":193861673},{"date":"2024-09-06","current":-4.347559,"twenty":-9.525571,"median":-8.069277,"eighty":-4.204574,"marketCap":183850037},{"date":"2024-09-13","current":-4.304513,"twenty":-9.489808,"median":-7.545298,"eighty":-4.204574,"marketCap":182029740},{"date":"2024-09-20","current":-3.93863,"twenty":-9.483818,"median":-7.11863,"eighty":-4.170873,"marketCap":166557212},{"date":"2024-09-27","current":-2.840979,"twenty":-9.431636,"median":-6.35886,"eighty":-4.072065,"marketCap":120139628},{"date":"2024-10-04","current":-2.56836,"twenty":-9.296072,"median":-5.58412,"eighty":-3.802872,"marketCap":108611078},{"date":"2024-10-11","current":-2.683147,"twenty":-9.199248,"median":-5.224584,"eighty":-3.740033,"marketCap":113465204},{"date":"2024-10-18","current":-3.034682,"twenty":-9.153032,"median":-4.873005,"eighty":-3.308736,"marketCap":128330966},{"date":"2024-10-25","current":-3.501004,"twenty":-9.080009,"median":-4.593919,"eighty":-3.325954,"marketCap":148050855},{"date":"2024-10-31","current":-3.651662,"twenty":-9.02741,"median":-4.557114,"eighty":-3.343172,"marketCap":154421896},{"date":"2024-11-08","current":-7.770049,"twenty":-9.018318,"median":-4.55561,"eighty":-3.379043,"marketCap":165040297},{"date":"2024-11-15","current":-7.870031,"twenty":-8.997775,"median":-4.571462,"eighty":-3.501004,"marketCap":167163977},{"date":"2024-11-22","current":-5.956085,"twenty":-8.989983,"median":-4.820607,"eighty":-3.501004,"marketCap":126510669},{"date":"2024-11-29","current":-6.413147,"twenty":-8.983995,"median":-4.921494,"eighty":-3.53544,"marketCap":136218922},{"date":"2024-12-06","current":-5.070528,"twenty":-8.981218,"median":-5.25247,"eighty":-3.595703,"marketCap":107700929},{"date":"2024-12-13","current":-4.784865,"twenty":-8.970201,"median":-5.21336,"eighty":-3.614356,"marketCap":101633271},{"date":"2024-12-20","current":-4.084989,"twenty":-8.95555,"median":-5.042643,"eighty":-3.644488,"marketCap":86767509},{"date":"2024-12-27","current":-3.799325,"twenty":-8.952556,"median":-4.89725,"eighty":-3.64221,"marketCap":80699851},{"date":"2025-01-03","current":-4.070706,"twenty":-8.886684,"median":-4.82416,"eighty":-3.64221,"marketCap":86464126},{"date":"2025-01-10","current":-4.427785,"twenty":-8.774403,"median":-4.734873,"eighty":-3.64221,"marketCap":94048699},{"date":"2025-01-17","current":-3.856458,"twenty":-8.71452,"median":-4.60353,"eighty":-3.6441,"marketCap":81913383},{"date":"2025-01-24","current":-3.727909,"twenty":-8.690567,"median":-4.558618,"eighty":-3.651662,"marketCap":79182936},{"date":"2025-01-31","current":-5.356192,"twenty":-8.660625,"median":-4.557114,"eighty":-3.694707,"marketCap":113768587},{"date":"2025-02-07","current":-4.256387,"twenty":-8.539337,"median":-4.55561,"eighty":-3.699343,"marketCap":90408104},{"date":"2025-02-14","current":-4.370652,"twenty":-8.47349,"median":-4.466458,"eighty":-3.699343,"marketCap":92835167},{"date":"2025-02-21","current":-4.470635,"twenty":-8.472282,"median":-4.477777,"eighty":-3.722196,"marketCap":94958847},{"date":"2025-02-28","current":-3.827892,"twenty":-8.245631,"median":-4.442068,"eighty":-3.730044,"marketCap":81306617},{"date":"2025-03-07","current":-3.670777,"twenty":-8.162365,"median":-4.40636,"eighty":-3.699343,"marketCap":77969405},{"date":"2025-03-14","current":-3.463671,"twenty":-8.134468,"median":-4.354733,"eighty":-3.698416,"marketCap":73570353},{"date":"2025-03-21","current":-2.203547,"twenty":-8.081254,"median":-4.304513,"eighty":-3.649772,"marketCap":58541914},{"date":"2025-03-28","current":-2.471704,"twenty":-7.90988,"median":-4.297339,"eighty":-3.6255,"marketCap":65666062},{"date":"2025-04-04","current":-1.632257,"twenty":-7.858605,"median":-4.256387,"eighty":-3.582221,"marketCap":43364381},{"date":"2025-04-11","current":-1.562303,"twenty":-7.846922,"median":-4.225597,"eighty":-3.501004,"marketCap":41505907},{"date":"2025-04-17","current":-1.842119,"twenty":-7.799915,"median":-4.189726,"eighty":-3.364695,"marketCap":48939801},{"date":"2025-04-25","current":-2.086958,"twenty":-7.727199,"median":-4.165203,"eighty":-3.259602,"marketCap":55444458},{"date":"2025-05-02","current":-2.366773,"twenty":-7.630073,"median":-4.156405,"eighty":-3.056205,"marketCap":62878352},{"date":"2025-05-09","current":-1.698098,"twenty":-7.560926,"median":-4.127838,"eighty":-2.911286,"marketCap":55444458},{"date":"2025-05-16","current":-1.907406,"twenty":-7.545298,"median":-4.116978,"eighty":-2.799369,"marketCap":62278559},{"date":"2025-05-23","current":-1.964344,"twenty":-7.500386,"median":-4.077848,"eighty":-2.746856,"marketCap":64137621},{"date":"2025-05-30","current":-2.011792,"twenty":-7.329718,"median":-4.070706,"eighty":-2.683147,"marketCap":65686838},{"date":"2025-06-06","current":-2.040261,"twenty":-7.099247,"median":-4.06458,"eighty":-2.616276,"marketCap":66616369},{"date":"2025-06-13","current":-2.05924,"twenty":-6.976473,"median":-4.013573,"eighty":-2.54373,"marketCap":67236056},{"date":"2025-06-20","current":-2.030771,"twenty":-6.805634,"median":-3.979786,"eighty":-2.387759,"marketCap":66306526},{"date":"2025-06-27","current":-4.033073,"twenty":-6.650207,"median":-3.970723,"eighty":-2.387759,"marketCap":131683521},{"date":"2025-07-03","current":-4.374698,"twenty":-6.513129,"median":-3.970723,"eighty":-2.471704,"marketCap":142837890},{"date":"2025-07-11","current":-3.738896,"twenty":-6.413147,"median":-3.970723,"eighty":-2.503792,"marketCap":122078370},{"date":"2025-07-18","current":-3.530125,"twenty":-6.413147,"median":-3.966646,"eighty":-2.541658,"marketCap":115261811},{"date":"2025-07-25","current":-3.805323,"twenty":-6.298881,"median":-3.947535,"eighty":-2.546837,"marketCap":124247275},{"date":"2025-08-01","current":-3.387782,"twenty":-6.198899,"median":-3.902759,"eighty":-2.561185,"marketCap":110614158},{"date":"2025-08-08","current":-3.368802,"twenty":-6.1132,"median":-3.885025,"eighty":-2.56836,"marketCap":109994470},{"date":"2025-08-15","current":-2.391434,"twenty":-6.1132,"median":-3.856458,"eighty":-2.546837,"marketCap":101332133},{"date":"2025-08-22","current":-2.596205,"twenty":-6.1132,"median":-3.856458,"eighty":-2.541658,"marketCap":110008891},{"date":"2025-08-29","current":-2.545012,"twenty":-6.033244,"median":-3.838191,"eighty":-2.530385,"marketCap":107839701},{"date":"2025-09-05","current":-2.74247,"twenty":-6.003302,"median":-3.805323,"eighty":-2.498872,"marketCap":116206575},{"date":"2025-09-12","current":-3.115445,"twenty":-5.964031,"median":-3.793648,"eighty":-2.525066,"marketCap":132010669},{"date":"2025-09-19","current":-2.881421,"twenty":-5.898952,"median":-3.776855,"eighty":-2.539403,"marketCap":122094374},{"date":"2025-09-26","current":-2.632771,"twenty":-5.861816,"median":-3.757875,"eighty":-2.544341,"marketCap":111558312},{"date":"2025-10-03","current":-3.28365,"twenty":-5.684705,"median":-3.738896,"eighty":-2.546472,"marketCap":139138005},{"date":"2025-10-10","current":-1.257879,"twenty":-5.595667,"median":-3.729992,"eighty":-2.525066,"marketCap":53300082},{"date":"2025-10-17","current":-1.060422,"twenty":-5.58412,"median":-3.727909,"eighty":-2.468814,"marketCap":44933209},{"date":"2025-10-24","current":-1.060422,"twenty":-5.516043,"median":-3.699343,"eighty":-2.388509,"marketCap":44933209},{"date":"2025-10-31","current":-1.075048,"twenty":-5.447334,"median":-3.691448,"eighty":-2.317303,"marketCap":45552977},{"date":"2025-11-07","current":-1.111614,"twenty":-5.371836,"median":-3.676368,"eighty":-2.244599,"marketCap":47102398},{"date":"2025-11-14","current":-0.828708,"twenty":-5.321912,"median":-3.651662,"eighty":-2.178806,"marketCap":42454135},{"date":"2025-11-21","current":-0.782205,"twenty":-5.233356,"median":-3.64221,"eighty":-2.124921,"marketCap":40071826},{"date":"2025-11-28","current":-0.819751,"twenty":-5.18765,"median":-3.621859,"eighty":-2.093402,"marketCap":41995273},{"date":"2025-12-05","current":-0.757174,"twenty":-5.110521,"median":-3.608617,"eighty":-2.055444,"marketCap":38789527},{"date":"2025-12-12","current":-0.719628,"twenty":-5.037066,"median":-3.577936,"eighty":-2.025264,"marketCap":36866080},{"date":"2025-12-15","current":-0.682083,"twenty":-5.025912,"median":-3.570795,"eighty":-2.015962,"marketCap":34942632}],"updateTime":1765879118541},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SKYE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2590537288","title":"Skye Bioscience Faces Investor Class Action Over Securities Fraud Allegations","url":"https://stock-news.laohu8.com/highlight/detail?id=2590537288","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590537288?lang=en_us&edition=fundamental","pubTime":"2025-12-11 03:47","pubTimestamp":1765396037,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against Skye Bioscience Inc., alleging securities fraud that affected investors who purchased shares between November 4, 2024, and October 3, 2025. The legal action claims that shareholders suffered financial losses due to the company's alleged misconduct. The case is being handled by the law firm Levi & Korsinsky, which has a history of representing investors in securities litigation and has secured significant recoveries for clients in previous cases. Investors who suffered losses during the specified period are encouraged to seek information about their rights and potential participation in the lawsuit.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL6Q2QZj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2585461547","title":"Skye Bioscience Unveils Presentation Highlighting Nimacimab’s Potential to Enhance Obesity Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2585461547","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585461547?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:04","pubTimestamp":1763985851,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc. has provided an update on the development of nimacimab, a novel therapeutic candidate for obesity and metabolic diseases. According to the presentation, nimacimab is positioned as a complementary treatment to existing GLP-1 therapies, offering approximately 3% additional weight loss when used in combination with semaglutide over 26 weeks. The data also indicate a lower rate of post-treatment weight rebound and a favorable body composition profile compared to GLP-1 monotherapy. The company highlights nimacimab's differentiated peripheral CB1 mechanism, which does not increase gastrointestinal or neuropsychiatric adverse events in combination regimens. Skye Bioscience reports a clear pharmacokinetic and exposure-response profile from Phase 2a studies and is planning further evaluation at higher doses. Nimacimab is presented as suitable for both patients who do not respond to or tolerate GLP-1 therapies and for those seeking enhanced weight loss outcomes. You can acce","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL8JPPYQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2585615834","title":"Skye Bioscience to Participate in Major Healthcare Investment Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2585615834","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585615834?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:01","pubTimestamp":1763985661,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc. will participate in several upcoming investment conferences, including the Citi Global Healthcare Conference in Miami with 1x1 meetings on December 2, the Evercore Annual Healthcare Conference in Coral Gables featuring a fireside chat on December 3 at 12:55 pm ET and 1x1 meetings, and the Piper Sandler Annual Healthcare Conference in New York with a fireside chat on December 4 at 11:30 am ET and 1x1 meetings. Webcasts of the events will be available on Skye's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief via Newsfile  on November 24, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDLbnvhXW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1244550221.USD","IE00BSNM7G36.USD","LU0130517989.USD","BK4127","BK4559","LU1366192091.USD","EVR","LU0170899867.USD","LU1267930227.SGD","BK4207","LU1791807156.HKD","LU0130102774.USD","LU2125154935.USD","LU2236285917.USD","LU1162221912.USD","LU2417539215.USD","BK4585","LU0310800965.SGD","BK4139","LU0098860793.USD","LU0052756011.USD","PIPR","SKYE","LU2462157665.USD","LU0072461881.USD","BK4588","LU0106831901.USD","LU1201861249.SGD","LU0162691827.USD","LU0648001328.SGD","BK4504","LU0980610538.SGD","LU2456880835.USD","BK4534","LU2125154778.USD","BK4566","LU0128525689.USD","LU1668664300.SGD","LU2360032135.SGD","LU1244550577.SGD","LU0320765646.SGD","LU1244550494.USD","LU0477156953.USD"],"gpt_icon":0},{"id":"2584901102","title":"Skye Bioscience Showcases New Obesity Drug Data Highlighting Add-On Benefits to GLP-1 Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2584901102","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584901102?lang=en_us&edition=fundamental","pubTime":"2025-11-20 12:01","pubTimestamp":1763611294,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc. has highlighted new data on its investigational obesity treatment, nimacimab, in a recent corporate presentation. According to the company, nimacimab is designed to complement existing GLP-1 therapies, providing approximately 3% additional weight loss over semaglutide alone at 26 weeks, with continued benefit over time. The presentation notes that nimacimab may offer more durable weight loss, with a lower post-treatment rebound rate and a favorable body-composition profile compared to GLP-1 monotherapy. The combination of nimacimab with incretin therapies was reported to show no increase in gastrointestinal side effects or neuropsychiatric adverse events. Skye Bioscience positions nimacimab as a differentiated, combination-friendly option with a peripheral CB1 mechanism, targeting both GLP-1 non-responders and those seeking enhanced weight loss outcomes. The company also reported a clear pharmacokinetic and exposure-response understanding from Phase 2a trials, supp","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL4DtPlJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2583303159","title":"Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR) and Skye Bioscience (SKYE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583303159","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583303159?lang=en_us&edition=fundamental","pubTime":"2025-11-12 23:50","pubTimestamp":1762962610,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Voyager Therapeutics (VYGR – Research Report) and Skye Bioscience...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-voyager-therapeutics-vygr-and-skye-bioscience-skye-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-voyager-therapeutics-vygr-and-skye-bioscience-skye-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR","BK4139","BK4137","BK4588","BK4585","LU0029874061.USD","LU0128526141.USD","SKYE","XLV","HCSG","LABU","XBI","BK4581"],"gpt_icon":0},{"id":"2582237960","title":"Oppenheimer Sticks to Their Buy Rating for Skye Bioscience (SKYE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582237960","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582237960?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:57","pubTimestamp":1762952221,"startTime":"0","endTime":"0","summary":"In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Skye Bioscience, with a price target of $10.00. According to TipR...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oppenheimer-sticks-to-their-buy-rating-for-skye-bioscience-skye-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oppenheimer-sticks-to-their-buy-rating-for-skye-bioscience-skye-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","SKYE"],"gpt_icon":0},{"id":"2582807498","title":"Press Release: Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2582807498","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582807498?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:01","pubTimestamp":1762808460,"startTime":"0","endTime":"0","summary":"-- Topline nimacimab Phase 2a study data showed clinically meaningful weight. after 26 weeks of treatment; the data demonstrated a clean. neuropsychiatric safety profile and no increase in gastrointestinal. -- Nimacimab plus semaglutide showed additional reduction in waist. period in patients treated with nimacimab plus semaglutide vs.\"As we obtain additional data from our CBeyond Phase 2a study, a holistic review provides us with additional confidence that nimacimab's biology is active and has the potential to fill notable gaps in the obesity and overweight landscape in order to support a healthier weight loss journey for patients,\" said Punit Dhillon, President & CEO of Skye. \"With the positive combination data, we are shifting our focus to a combination development pathway while simultaneously planning to further understand nimacimab's potential benefit in a monotherapy setting. We anticipate that forthcoming biomarker data and the readout from the 26-week extension will continue to","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4099","03160","BK4555","BK4232","BK4139","BK4588","TM","BK4604","R","BK4585","BK4022"],"gpt_icon":0},{"id":"2581832638","title":"Analysts Offer Insights on Healthcare Companies: Skye Bioscience (SKYE) and IN8bio (INAB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581832638","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581832638?lang=en_us&edition=fundamental","pubTime":"2025-11-08 06:10","pubTimestamp":1762553411,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Skye Bioscience (SKYE – Research Report) and IN8bio ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-skye-bioscience-skye-and-in8bio-inab-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-skye-bioscience-skye-and-in8bio-inab-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SKYE","BK4588","BK4137","BK4539","HCSG","LABU","LU0128526141.USD","INAB","LU0029874061.USD","XBI","BK4139","XLV","BK4585","BK4581"],"gpt_icon":0},{"id":"2580294221","title":"Skye Bioscience Inc  expected to post a loss of 31 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580294221","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580294221?lang=en_us&edition=fundamental","pubTime":"2025-11-03 19:34","pubTimestamp":1762169656,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc  expected to post a loss of31cents a share - Earnings Preview Skye Bioscience Inc SKYE.OQ SKYE.O is expected to  show no change in quarterly revenue when it reports  results on Nov","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nL8N3WF0R9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SKYE"],"gpt_icon":0},{"id":"2573936624","title":"Skye Bioscience Inc : Piper Sandler Cuts Target Price to $13 From $20","url":"https://stock-news.laohu8.com/highlight/detail?id=2573936624","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573936624?lang=en_us&edition=fundamental","pubTime":"2025-10-07 11:47","pubTimestamp":1759808878,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nFWN3VN2NX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SKYE"],"gpt_icon":0},{"id":"2573890129","title":"Citizens JMP Remains a Buy on Skye Bioscience (SKYE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2573890129","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573890129?lang=en_us&edition=fundamental","pubTime":"2025-10-07 06:05","pubTimestamp":1759788304,"startTime":"0","endTime":"0","summary":"Citizens JMP analyst Jonathan Wolleben maintained a Buy rating on Skye Bioscience today and set a price target of $4.00. The company’s shares close...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/citizens-jmp-remains-a-buy-on-skye-bioscience-skye-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/citizens-jmp-remains-a-buy-on-skye-bioscience-skye-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","JMP","SKYE","BK4139"],"gpt_icon":0},{"id":"2573060202","title":"Craig Hallum Downgrades Skye Bioscience to Hold From Buy, $2 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2573060202","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573060202?lang=en_us&edition=fundamental","pubTime":"2025-10-07 02:21","pubTimestamp":1759774912,"startTime":"0","endTime":"0","summary":"Price: 1.90, Change: -2.85, Percent Change: -60.04","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","SKYE"],"gpt_icon":0},{"id":"2573011246","title":"Skye Bioscience downgraded to Hold from Buy at Craig-Hallum","url":"https://stock-news.laohu8.com/highlight/detail?id=2573011246","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573011246?lang=en_us&edition=fundamental","pubTime":"2025-10-07 00:15","pubTimestamp":1759767327,"startTime":"0","endTime":"0","summary":"Craig-Hallum downgraded Skye Bioscience (SKYE) to Hold from Buy with a $2 price target Published first on TheFly – the ultimate source for real-tim...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/skye-bioscience-downgraded-to-hold-from-buy-at-craig-hallum-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/skye-bioscience-downgraded-to-hold-from-buy-at-craig-hallum-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2573031056","title":"Skye Bioscience downgraded to Neutral from Overweight at Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2573031056","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573031056?lang=en_us&edition=fundamental","pubTime":"2025-10-06 22:20","pubTimestamp":1759760406,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald downgraded Skye Bioscience (SKYE) to Neutral from Overweight with a price target of $2, down from $14. Published first on TheFly ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/skye-bioscience-downgraded-to-neutral-from-overweight-at-cantor-fitzgerald-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/skye-bioscience-downgraded-to-neutral-from-overweight-at-cantor-fitzgerald-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SKYE"],"gpt_icon":0},{"id":"2573671720","title":"Skye Bioscience Shares Slide as Weight-Loss Drug Candidate Misses Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2573671720","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573671720?lang=en_us&edition=fundamental","pubTime":"2025-10-06 19:41","pubTimestamp":1759750860,"startTime":"0","endTime":"0","summary":"Skye Bioscience shares fell sharply Monday in premarket trading after the company said its weight-loss drug didn't meet its clinical targets.Shares traded 60% lower at $1.91 ahead of the morning bell.The clinical-stage biotechnology company on Monday said top-line data from its Phase 2a CBeyond proof-of-concept study of the compound nimacimab didn't meet primary weight-loss endpoints as a stand-alone therapy.The San Diego company also said combining nimacimab with semaglutide, the active ingredient in Ozempic and Wegovy used to treat type 2 diabetes, led to significantly greater weight loss at 26 weeks compared with semaglutide alone. Skye said this finding supports potential further studies to evaluate combinations of nimacimab and incretin-based therapies.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Skye Bioscience Shares Slide as Weight-Loss Drug Candidate Misses Primary Endpoint","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2573671589","title":"Skye Bioscience says nimacimab did not meet primary endpoint in CBeyond study","url":"https://stock-news.laohu8.com/highlight/detail?id=2573671589","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573671589?lang=en_us&edition=fundamental","pubTime":"2025-10-06 19:16","pubTimestamp":1759749376,"startTime":"0","endTime":"0","summary":"Skye Bioscience (SKYE) announced the topline data from its 26-week Phase 2a CBeyond proof-of-concept study of nimacimab, its peripherally-restricte...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/skye-bioscience-says-nimacimab-did-not-meet-primary-endpoint-in-cbeyond-study-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/skye-bioscience-says-nimacimab-did-not-meet-primary-endpoint-in-cbeyond-study-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SKYE"],"gpt_icon":0},{"id":"2573449679","title":"Skye Bioscience's obesity drug fails to meet main goal of mid-stage study","url":"https://stock-news.laohu8.com/highlight/detail?id=2573449679","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573449679?lang=en_us&edition=fundamental","pubTime":"2025-10-06 19:08","pubTimestamp":1759748906,"startTime":"0","endTime":"0","summary":"Skye Bioscience's obesity drug fails to meet main goal of mid-stage studyOct 6 (Reuters) - Skye Bioscience SKYE.O said on Monday its experimental obesity drug did not meet the main goal of a mid-stage","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nL3N3VN0JP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2573679448","title":"BRIEF-Skye Bioscience reports early trial data for Cbeyond combo and solo use of Nimacimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2573679448","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573679448?lang=en_us&edition=fundamental","pubTime":"2025-10-06 19:08","pubTimestamp":1759748904,"startTime":"0","endTime":"0","summary":"BRIEF-Skye Bioscience reports early trial data for Cbeyond combo and solo use of NimacimabOct 6 (Reuters) - Skye Bioscience Inc SKYE.O:SKYE BIOSCIENCE REPORTS TOPLINE CBEYOND PHASE 2A DATA FROM NIMACI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nTUA6VGJ6S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2573799206","title":"Skye Bioscience Inc - Expects to Report Data From Extension Study in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2573799206","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573799206?lang=en_us&edition=fundamental","pubTime":"2025-10-06 19:00","pubTimestamp":1759748401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nTUA6VGJ6S:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2573795066","title":"Skye Bioscience Inc - Additional Weight Loss With Nimacimab and Semaglutide Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2573795066","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573795066?lang=en_us&edition=fundamental","pubTime":"2025-10-06 19:00","pubTimestamp":1759748401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nTUA6VGJ6S:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SKYE","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":47,"code":"91000000","status":"200"}]}}